Short-Term Inpatient Pharmacotherapy of Schizophrenia

REFERENCES

• American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(suppl 4):1–63.
   Google Scholar
• Anonymous. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(suppl 2):25–40S.
   Google Scholar
• Lehman AF, Steinwachs DM. Translating research into prac- tice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24:1–10.
   PubMed Web of Science ®Google Scholar
• Anonymous. Treatment of schizophrenia 1999: the expert consensus guideline series. J Clin Psychiatry 1999;60(suppl 11):3–80.
   Google Scholar
• Anonymous. Treatment of schizophrenia: the expert consen- sus guideline series. J Clin Psychiatry 1996;57(suppl 12B): 3–58.
   Google Scholar
• Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizo- phrenia algorithms. J Clin Psychiatry 1999;60:649–57.
   PubMed Web of Science ®Google Scholar
• Osser DN. Treatment-resistant problems. In: Tupin JP, Shader RI, Harnett DS, eds. Handbook of clinical psycho- pharmacology. 2nd ed. New York: Aronson, 1988:269–328.
   Google Scholar
• Osser DN. A systematic approach to pharmacotherapy in pa- tients with neuroleptic-resistant psychoses. Hosp Commu- nity Psychiatry 1989;40:921–7.
   Google Scholar
• Osser DN, Patterson RD. Pharmacotherapy of schizophre- nia, I [Acute treatment] and II [An algorithm for neuroleptic- resistant patients]. In: Soreff SM, ed. Handbook for the treat- ment of the seriously mentally ill. Seattle: Hogrefe & Huber, 1996:91–155.
   Google Scholar
• Osser DN, Zarate CA Jr. Consultant for the pharmacother- apy of schizophrenia. Psychiatr Ann 1999;29:252–67.
   Google Scholar
• Osser DN. The neuroleptic-resistant psychosis psychophar- macology consultant: an expert system. Version 4.0. Lexing- ton, Massachusetts: Mental Health Connections, 1995.
   Google Scholar
• Osser DN, Patterson RD. Consultant for the pharmacother- apy of schizophrenia. Lexington, Massachusetts: Mental Health Connections, 2000 [Available on the World Wide Web: http://mhc.com/Algorithms].
   Google Scholar
• Ereshefsky L. Pharmacologic and pharmacokinetic consider- ations in choosing an antipsychotic. J Clin Psychiatry 1999; 60(suppl 10):20–30.
   Google Scholar
• Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treat- ment: patterns of psychotropic drug use in Austrian psychi- atric clinics. Eur Psychiatry 1999;14:33–40.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(suppl 10):31–41.
   Google Scholar
• Stahl SM. Antipsychotic polypharmacy, part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425–6.
   PubMed Web of Science ®Google Scholar
• DeQuardo JR. Recommended haloperidol and risperidone doses in first-episode psychosis [Commentary reply]. J Clin Psychiatry 1999;60:794–5.
   Google Scholar
• Hughes DH. Acute psychopharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999;50:1135–7.
   PubMedGoogle Scholar
• Binder RL, McNiel DE. Emergency psychiatry: contempo- rary practices in managing acutely violent patients in 20 psy- chiatric emergency rooms. Psychiatr Serv 1999;50:1553–4.
   PubMed Web of Science ®Google Scholar
• Reischel UA, Shih RD. Evaluation and management of psy- chotic patients in the emergency department. Hosp Phys 1999;14:26–38.
   Google Scholar
• Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency depart- ment study. Am J Emerg Med 1997;15:335–40.
   PubMed Web of Science ®Google Scholar
• Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989;146:1598–601.
   PubMed Web of Science ®Google Scholar
• Hyman SE. Acute psychoses and catatonia. In: Hyman SE, Tesar GE, eds. Manual of psychiatric emergencies. 3rd ed. Boston: Little, Brown, 1994:143–57.
   Google Scholar
• Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br J Clin Pharmacol 1981;11(suppl 1):99–104S.
   Google Scholar
• Rothschild AJ, Shindul-Rothschild JA, Viguera A, Murray M, Brewster S. Comparison of the frequency of behavioral dis- inhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients. J Clin Psychopharmacol 2000;20:7–11.
   PubMedGoogle Scholar
• Dietch JT, Jennings RK. Aggressive dyscontrol in patients treated with benzodiazepines. J Clin Psychiatry 1988;49:184–8.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Woods SW, Groves JE, Klerman GL. Emer- gence of hostility during alprazolam treatment. Am J Psychi- atry 1984;141:792–3.
   PubMed Web of Science ®Google Scholar
• Chambers RA, Druss BG. Droperidol: efficacy and side ef- fects in psychiatric emergencies. J Clin Psychiatry 1999;60:664–7.
   PubMed Web of Science ®Google Scholar
• Thomas H Jr, Schwartz E, Petrilli R. Droperidol versus halo- peridol for chemical restraint of agitated and combative pa- tients. Ann Emerg Med 1992;21:407–13.
   Google Scholar
• Derlet RW, Rice P, Horowitz BZ, Lord RV. Amphetamine tox- icity: experience with 127 cases. J Emerg Med 1989;7:157–61.
   PubMedGoogle Scholar
• Dorevitch A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular flunitrazepam versus intramuscular halo- peridol in the emergency treatment of aggressive psychotic behavior. Am J Psychiatry 1999;156:142–4.
   PubMed Web of Science ®Google Scholar
• Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991;52:177–80.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquili- zation with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 1993;38(suppl 4): S114–21.
   Google Scholar
• Neborsky R, Janowsky D, Munson E, Depry D. Rapid treat- ment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. Arch Gen Psychiatry 1981;38:195–9.
   PubMed Web of Science ®Google Scholar
• Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophy- laxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol 1987;7:164–6.
   PubMed Web of Science ®Google Scholar
• Arana GW, Goff DC, Baldessarini RJ, Keepers GA. Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. Am J Psychiatry 1988;145:993–6.
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole com- pared to conventional antipsychotics and placebo: a meta- analysis of randomized controlled trials. Schizophr Res 1999; 35:51–68.
   PubMed Web of Science ®Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371–6.
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Review: quetiapine leads to fewer withdrawals because of adverse ef- fects in schizophrenia [Abstract, with commentary by C Bar- bui]. Evidence-Based Ment Health 1999;2:52.
   Google Scholar
• Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Library 4. Oxford, England: Up- date Software, 2000.
   Google Scholar
• Gilbody SM, Song FJ, Eastwood AJ, Sutton A. The causes, consequences, and detection of publication bias in psychiatry. Acta Psychiatr Scand 2000;102:241–9.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Beauclair L, Belanger MC. An- tipsychotic tolerance, rebound, and supersensitivity psycho- sis with quetiapine. Presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, Illinois, May 2000.
   Google Scholar
• Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clo- zapine or quetiapine. Am J Psychiatry 1999;156:876–84.
   PubMed Web of Science ®Google Scholar
• Reinstein MJ, Bari MA, Ginsberg LD, Sandler NH, Mullen JA. Quetiapine fumarate and risperidone in outpatients with psychotic disorders: results of the QUEST trial. Presented at the 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
   Google Scholar
• Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Library 4. Oxford, England: Update Software, 2000.
   Google Scholar
• Kennedy E, Song F, Hunter R, Clark A, Gilbody S. Risperi- done versus typical antipsychotic medication for schizophre- nia. Cochrane Library 4. Oxford, England: Update Soft- ware, 2000.
   Google Scholar
• Adams C. Typicals vs atypicals—bad science in the BMJ [Electronic letter]. BMJ 2000 [Available on the World Wide Web: www.bmj.com/cgi/eletters/321/7273/1371#EL7].
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine ver- sus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407–18.
   PubMed Web of Science ®Google Scholar
• Conley RR, Brecher MB. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffec- tive disorder. Presented at the 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, May 1999.
   Google Scholar
• Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658–63.
   PubMed Web of Science ®Google Scholar
• Laux G, Ko¨nig W, Jones M. Inpatient treatment of schizo- phrenia: a study of two leading atypical antipsychotics [Ab- stract]. Schizophr Res 2000;41:38.
   Google Scholar
• Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308–13.
   PubMed Web of Science ®Google Scholar
• Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry 1999;60:771–5.
   PubMed Web of Science ®Google Scholar
• Lane HY, Chiu WC, Chou JCY, Wu ST, Su MH, Chang WH. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000;61:209–14.
   Google Scholar
• Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull 1999;25:721–9.
   PubMed Web of Science ®Google Scholar
• Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olan- zapine trial. Neuropsychopharmacology 1996;14:111–23.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizo- phreniform disorders: results of an international collabora- tive trial. Am J Psychiatry 1997;154:457–65.
   PubMed Web of Science ®Google Scholar
• Kelly C, McCreadie RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999;156:1751–7.
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizo- phrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233–46.
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia: a high- and low- dose double-blind comparison with placebo. Arch Gen Psychi- atry 1997;54:549–57.
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperi- done on the five dimensions of schizophrenia derived by fac- tor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538–46.
   PubMed Web of Science ®Google Scholar
• Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995;91:271–7.
   PubMed Web of Science ®Google Scholar
• Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85:295–305.
   PubMed Web of Science ®Google Scholar
• Høyberg OJ, Fensbo C, Remvig J, Lingjærde O, Sloth- Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395–402.
   PubMed Web of Science ®Google Scholar
• Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265–73.
   PubMed Web of Science ®Google Scholar
• Copolov DL, Link CGG, Kowalcyk B. A multicentre, double- blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000;30:95–105.
   PubMed Web of Science ®Google Scholar
• Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypi- cal antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158–69.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a com- prehensive research synthesis. Am J Psychiatry 1999;156:1686–96.
   PubMed Web of Science ®Google Scholar
• Knegtering H, Blijd C, Boks M. Sexual dysfunction and pro- lactin levels in patients using risperidone or olanzapine [Ab- stract]. Schizophr Res 2000;41:196.
   Google Scholar
• Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, et al. Interim results of a randomized con- trolled trial of haloperidol, risperidone, and olanzapine in psychotic youth. Presented at the 38th annual meeting of the American College of Neuropsychopharmacology, Acapulco, Mexico, December 1999.
   Google Scholar
• Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999;156:79–87.
   PubMed Web of Science ®Google Scholar
• McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psy- chotic disorders. J Clin Psychiatry 1999;60:292–8.
   PubMed Web of Science ®Google Scholar
• Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics—risperidone and olanza- pine in the elderly. Ann Clin Psychiatry 1999;11:113–8.
   PubMedGoogle Scholar
• Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60:767–70.
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [Letter]. Am J Psychiatry 1999;156: 1471.
   PubMed Web of Science ®Google Scholar
• Grundy SM. Hypertriglyceridemia, atherogenic dyslipide- mia, and the metabolic syndrome. Am J Cardiol 1998; 81(4A):18–25B.
   Google Scholar
• Steingard S, Allen M, Schooler NR. A study of the pharmaco- logic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 1994;55:470–2.
   PubMed Web of Science ®Google Scholar
• Lamb HR. Structure: the neglected ingredient of community treatment. Arch Gen Psychiatry 1980;37:1224–8.
   PubMed Web of Science ®Google Scholar
• Kopelowicz A, Liberman RP, Mintz J, Zarate R. Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 1997; 154:424–5.
   PubMed Web of Science ®Google Scholar
• Sperry L. Psychopharmacology and psychotherapy: strate- gies for maximizing treatment outcomes. New York: Brun- ner/Mazel, 1995.
   Google Scholar
• Viguera AC, Baldessarini RJ, Hegarty JD, Van Kammen DP, Tohen M. Clinical risk following abrupt and gradual with- drawal of maintenance neuroleptic treatment. Arch Gen Psy- chiatry 1997;54:49–55.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antipsychotic polypharmacy, part 2: Tips on use and misuse. J Clin Psychiatry 1999;60:506–7.
   Google Scholar
• Marder SR. Newer antipsychotics in treatment-resistant schizophrenia. Biol Psychiatry 1999;45:383–4.
   PubMedGoogle Scholar
• Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syn- drome. Am J Psychiatry 1998;155:751–60.
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind compari- son with chlorpromazine. Arch Gen Psychiatry 1988;45:789–96.
   PubMed Web of Science ®Google Scholar
• Tupala E, Niskanen L, Tiihonen J. Transient syncope and ECG changes associated with the concurrent administration of clozapine and diazepam [Letter]. J Clin Psychiatry 1999; 60:619–20.
   Google Scholar
• Faisal I, Lindenmayer JP, Taintor Z, Cancro R. Clozapine- benzodiazepine interactions [Letter]. J Clin Psychiatry 1997; 58:547–8.
   Google Scholar
• Peacock L, Gerlach J. Clozapine treatment in Denmark: con- comitant psychotropic medication and hematologic monitor- ing in a system with liberal usage practices. J Clin Psychia- try 1994;55:44–9.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997;58(suppl 10):63–72.
   Google Scholar
• Shiovitz TM, Welke TL, Tigel PD, Anand R, Hartman RD, Sramek JJ, et al. Cholinergic rebound and rapid onset psy- chosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591–5.
   PubMed Web of Science ®Google Scholar
• Stanilla JK, De Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997;58:252–5.
   Google Scholar
• Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs [Letter]. Arch Gen Psychiatry 1995;52:1071–2.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Blyler CR, Heinssen RK. Determinants of medi- cation compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637–51.
   PubMed Web of Science ®Google Scholar
• Love RC, Conley RR, Kelly DL, Bartko JJ. A comparison of rehospitalization rates between patients treated with atypi- cal antipsychotics and those treated with depot antipsychot- ics. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 1998.
   Google Scholar
• Littrell KH. Patients switched from depot antipsychotics to oral risperidone or olanzapine: an open-label randomized trial. Presented at the 152nd Annual Meeting of the Amer- ican Psychiatric Association, Washington, DC, May 1999.
   Google Scholar
• Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61:344–8.
   PubMed Web of Science ®Google Scholar
• Wei FC, Jann MW, Lin HN, Piao-Chien C, Chang WH. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psy- chiatry 1996;57:298–302.
   Google Scholar
• Currier GW, Simpson GM. Risperidone oral solution versus intramuscular haloperidol for rapid control of psychotic agi- tation. Presented at the 38th annual meeting of the Ameri- can College of Neuropsychopharmacology, Acapulco, Mexico, December 1999.
   Google Scholar
• Rosebush PI, Mazurek MF. Neurologic side effects in neuro- leptic-naive patients treated with haloperidol or risperidone. Neurology 1999;52:782–5.
   PubMedGoogle Scholar
• Levinson DF, Umapathy C, Musthaq M. Treatment of schizo- affective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999;156:1138–48.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al. Time course and biologic correlates of treatment re- sponse in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369–76.
   PubMed Web of Science ®Google Scholar
• Wassef AA, Dott SG, Harris A, Brown A, O’Boyle M, Meyer WJ III, et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 1999; 19:222–32.
   PubMedGoogle Scholar
• Christison GW, Kirch DG, Wyatt RJ. When symptoms per- sist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991;17:217–45.
   PubMed Web of Science ®Google Scholar
• Wassef AA, Dott SG, Harris A, Brown A, O’Boyle M, Meyer WJ III, et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20:357–61.
   PubMed Web of Science ®Google Scholar
• Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991;17:649–57.
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825–35.
   PubMed Web of Science ®Google Scholar
• Fanous A, Lindenmayer JP. Schizophrenia and schizoaffec- tive disorder treated with high doses of olanzapine [Letter]. J Clin Psychopharmacol 1999;19:275–6.
   PubMed Web of Science ®Google Scholar
• Wilson DR. High dose olanzapine and prolactin levels. Pre- sented at the 51st American Psychiatric Association Institute on Psychiatric Services, New Orleans, October 1999.
   Google Scholar
• Wassef AA, Hafiz NG, Hampton D, Molloy M. Divalproex so- dium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications. J Clin Psychopharmacol 2001;21:21–6.
   PubMed Web of Science ®Google Scholar
• Lerner Y, Mintzer Y, Shestatzky M. Lithium combined with haloperidol in schizophrenic patients. Br J Psychiatry 1988; 153:359–62.
   PubMed Web of Science ®Google Scholar
• Woods SW, Ziedonis DM, Sernyak MJ, Diaz E, Rosenheck RA. Characteristics of participants and nonparticipants in medication trials for treatment of schizophrenia. Psychiatr Serv 2000;51:79–84.
   PubMedGoogle Scholar